CClinicalTrials.gg
CompletedNCT04120337Updated Sep 28, 2021

Safe Access: Trial With RemovAid Device

An interventional study of RemovAid device + lidocaine patch and Standard technique + lidocaine injection in Removal of a Contraceptive Subdermal Implant, sponsored by RemovAid AS. Completed at 1 site in Uganda. Open to female participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-28.

Sponsored by RemovAid AS · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Female
01

Study summary

This randomized trial will compare different approaches to removing a subdermal contraceptive implant from the upper arm of 225 women in Uganda. The experimental approach is a hand-held device (RemovAid) that incises the skin and grasps the implant for extraction. Safety and efficacy endpoints will be compared to the traditional removal approach (scalpel, forceps, tweezers).

Read the detailed description

The trial assigns participants to one of three arms: RemovAid+lidocaine patch (n=75), RemovAid+lidocaine injection (n=75) or traditional approach+lidocaine injection(n=75). Complication rates in the different arms will be compared. Efficacy (successful implant removal) will be the secondary comparisons. Finally, pain during removal and duration of removal procedure will be compared. Participants will return to the clinic within 4 weeks of the removal procedure to record the healing process and final interventions (if any).

02

Conditions studied

  • Removal of a Contraceptive Subdermal Implant
03

In context

Lead sponsor

RemovAid AS is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • seeking voluntary removal of a one-rod subdermal implant
  • willing to sign an informed consent document
  • willing to be randomized to the new device vs. standard technique
  • willing to follow-up at the study clinic for any subsequent removal-related complications
  • willing to have any follow-up complications recorded and shared
  • has an implant that is completely and easily palpable
  • has an implant that is easily pinched and lifted
  • no known allergies to skin preparation products or local anesthetics

Exclusion criteria

Exclusion Criteria:

  • Implants that are not easily palpable
  • Previous failed implant removal
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    RemovAid Device + lidocaine patch

    Test device with lidocaine patch for local anesthesia

    Device: RemovAid device + lidocaine patch

  • Experimental
    RemovAid Device + lidocaine injection

    Test device with lidocaine injection for local anesthesia

    Device: RemovAid device + lidocaine injection

  • Active comparator
    Standard removal technique + lidocaine injection

    Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia

    Procedure: Standard technique + lidocaine injection

Interventions

  • DeviceRemovAid device + lidocaine patch

    The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.

  • ProcedureStandard technique + lidocaine injection

    Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.

  • DeviceRemovAid device + lidocaine injection

    The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.

06

What researchers measure

Primary outcomes

  1. Number of women who have post-removal complications -

    Complications will include unusual level of trauma to the skin (bruising/hematoma), excessive bleeding, use of sutures to repair skin after removal, inability to remove the implant, implant breakage or severing at time of removal, subsequent infection at the removal site, and other complications that may be noted by the investigator

    Time frame: 4 weeks

  2. Number of implants that are successfully removed

    The number of implants successfully removed i) without breaking the implant and without additional tools (scalpel, tweezers, or forceps), ii) without additional tools, iii) without the additional use of a scalpel.

    Time frame: 0-3 hours

Secondary outcomes

  1. Participant pain level

    Level of pain as recorded on 10cm visual analog scale from 0cm (No Pain) to 10cm (Worse Pain Imaginable) with higher numbers indicating worse outcomes

    Time frame: 0-3 hours

  2. Duration of removal procedure

    Number of minutes and seconds need to remove the implant

    Time frame: 0-3 hours

  3. Provider feedback on device on whether RemovAid device helped with removal of implant

    5-point Likert scale measuring from 1(Strongly Disagree), 2 (Disagree), 3 (Neutral), 4 (Agree), 5 (Strongly Agree) on whether RemovAid device helped with removal of implant with higher scores indicating better outcomes

    Time frame: 0-3 hours

  4. Provider feedback on device on ways the product helped or hindered implant removal

    Text responses on ways the product helped or hindered implant removal

    Time frame: 0-3 hours

07

Study locations

1 site
  • Kawempe Referral Hospital
    Kampala, Uganda
08

References and documents

Publications

  • Levine JP, Sinofsky FE, Christ MF; Implanon US Study Group. Assessment of Implanon insertion and removal. Contraception. 2008 Nov;78(5):409-17. doi: 10.1016/j.contraception.2008.06.016. Epub 2008 Sep 18. PubMed 18929739 ↗
  • Fraser IS. The challenges of location and removal of Implanon contraceptive implants. J Fam Plann Reprod Health Care. 2006 Jul;32(3):151-2. doi: 10.1783/147118906777888459. No abstract available. PubMed 16857065 ↗
  • Creinin MD, Kaunitz AM, Darney PD, Schwartz L, Hampton T, Gordon K, Rekers H. The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience. Contraception. 2017 Feb;95(2):205-210. doi: 10.1016/j.contraception.2016.07.012. Epub 2016 Jul 21. PubMed 27452317 ↗
  • Hubacher D, Byamugisha J, Kakaire O, Nalubwama H, Emtell Iwarsson K, Bratlie M, Chen PL, Gemzell-Danielsson K. Removal of a well-palpable one-rod subdermal contraceptive implant using a dedicated hand-held device or standard technique: a randomized, open-label, non-inferiority trial. Hum Reprod. 2022 Sep 30;37(10):2320-2333. doi: 10.1093/humrep/deac179. PubMed 35960174 ↗

Study documents

  • Statistical analysis plan · May 28, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Results and data will be archived in the Norwegian Social Science Data Services (NSD). Data will be made available after the primary results are published.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04120337
Lead sponsor
RemovAid AS
Collaborators
Karolinska Institutet, Mulago Hospital, Uganda, FHI 360
Responsible party
Sponsor
First posted
Oct 9, 2019
Start date
Dec 23, 2019
Primary completion
Nov 9, 2020
Completion
Apr 1, 2021
Last update
Sep 28, 2021

Study contacts

Kristina Gemzell-Danielsson, MD, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion